Navigation Links
FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Date:12/13/2010

ODIN study were presented earlier this year at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco. The study achieved its primary objective of demonstrating non-inferiority of PREZISTA/ritonavir once daily compared with twice daily.

PREZISTA Indication: AdultsPREZISTA, co-administered with ritonavir and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection.

This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from two controlled, Phase 3 trials of 48 weeks duration in antiretroviral treatment-naïve and treatment-experienced patients, and two controlled, Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients. In treatment-experienced adult patients, the following points should be considered when initiating therapy with PREZISTA/ritonavir:


  • Treatment history and, when available, genotypic or phenotypic testing, should guide the use of PREZISTA/ritonavir.

  • The use of other active agents with PREZISTA/ritonavir is associated with a greater likelihood of treatment response.
  • About the ODIN StudyODIN is a Phase 3b, randomized, open-label study that compared the efficacy, safety, and tolerability of PREZISTA/ritonavir 800/100 mg once daily versus PREZISTA/ritonavir 600/100 mg twice daily at week 48 in 590 treatment-experienced HIV-1-infected adult patients with no DRV RAMs (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V). Patients had HIV-1 RNA greater than 1,000 copies/mL and CD4 count greater than 50 cells/mm(3), and received a stable antiretroviral therapy regimen for greater than or equal to 12 weeks at screening. Patients received either once-daily (n=294) or twice-daily (n=296) PREZISTA/ritonavir plus optimized background regimen. The primary objective of the study was to demonstrate non-inferiority of PREZISTA/ritonavir
    '/>"/>

    SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... 2015 Research and Markets ( ... "Telemedicine and Mobile Healthcare Solutions, Services, and ... report to their offering. ... terms that pertain to the use of telecommunications ... clinical/non-clinical healthcare services. They form the ecosystem that ...
    (Date:3/3/2015)... RADNOR, Pa. , March 3, 2015 /PRNewswire/ ... of laboratory products, services and solutions, announced today ... England Biolabs®, Inc. (NEB®). This agreement allows VWR ... renowned technical support in the U.S. and Puerto ... to NEB,s products through VWR,s e-business platform, sales ...
    (Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., ... cell-derived islet replacement therapy for the treatment of diabetes ... Eugene Brandon , Director of Strategic Relations and ... summit showcases the latest in type 1 diabetes management ... are as follows: , , , Title:   ...
    Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3VWR Announces Expansion of Distribution Agreement with New England Biolabs 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
    (Date:3/4/2015)... Professionals with disabilities are eager to ... companies, according to a new Think Beyond the Label ... 235 professionals with disabilities , respondents also say they ... including ones that are geared to people with disabilities, ... ,     Online job search tools are used by ...
    (Date:3/4/2015)... 04, 2015 The medical device landscape ... management forgot – or ignored or didn't know – ... market based on physician input before proceeding to design ... specifically, founders – become so enamored of an innovative ... Will physicians use the device?” says Dr. Kathryn ...
    (Date:3/3/2015)... Anik Singal's Profit Academy - ... marketers has become the talk of the town ... surrounding the course's general release has garnered the ... her to review the program's content and publish ... biggest keys to success with Internet marketing is ...
    (Date:3/3/2015)... March 03, 2015 On February 21st, ... the fabulous EcoLuxe Lounge, a day-long event that features ... conscious products and services. Organized by Debbie Durkin and ... film placement producer, the EcoLuxe Lounge saw many notable ... roles on General Hospital, The Flash, Star Trek: Deep ...
    (Date:3/3/2015)... March 03, 2015 Findings could lead ... at UC Davis have developed and characterized a molecule ... causing them to self-destruct. This novel mechanism was found ... a usually fatal type of brain cancer – and ... , The article, to be published in the April ...
    Breaking Medicine News(10 mins):Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 2Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 3Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Anik Singal's Profit Academy - Review Of New IM Training Program Released 2Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4
    ... could actually be caused as a result of a defect ... after scientists have worked towards identifying important skin cancer genes ... scientists to look at thousands of genes at once, helping ... greater detail. There are over 200 different types of cancer ...
    ... ketoacidosis (DKA) is a life-threatening condition that frequently ... The critical factors in the treatment of DKA ... skillful fluid and electrolyte adjustment, and the initiation ... fluid volume has been achieved. Continuous low-dosage intravenous ...
    ... Anderson Cancer Center have found that weight gain or ... of prostrate cancer. ,The report is detailed in ... Research, corroborates findings of an earlier research that had ... Strom, Ph.D., an associate professor in the Department of ...
    ... Phase II study to 12 months confirm the significant effects ... patients with relapsing multiple sclerosis (MS). ,The data, ... both patient groups taking FTY720 (1.25 mg and 5 mg) ... of more than 50% during the first six months of ...
    ... chronic illness that requires continuing medical care and ... to reduce the risk of long-term complications//. As ... care practitioners are confronted with an ever-increasing tide ... Undiagnosed chronic kidney disease (CKD) is common in ...
    ... an ancient myth that coco bean can be used to treat ... limit the development of fluids that cause diarrhea//. ,The use ... 16th century by ancient South American and European cultures. Until now, ... bean or more specifically why it has been used in the ...
    Cached Medicine News:Health News:Novartis MS Drug Shows Promising Results 2Health News:Novartis MS Drug Shows Promising Results 3
    ... simple, effective method for determining color vision ... data which can be applied to many ... set consists of four trays containing a ... that have incremental hue variation on one ...
    ... D15 test evaluation has a choice ... caps with automatic creation 'horse-shoe' diagrams, ... deficiency analysis, calculation of color confusion ... eye selection (OD, OS, OU) and ...
    ... Farnsworth D15 test is used ... color defect vs normal. Farnsworth ... which permit the patient to ... Then the box is closed ...
    HRR/Amsler book combo with occluding glasses....
    Medicine Products: